See-Mode raises US$7m Series A funds led by MassMutual Ventures

Sharanya Pillai

Sharanya Pillai

Published Thu, Aug 20, 2020 · 01:50 PM

SEE-MODE Technologies, a medtech startup based in Singapore and Australia, has raised US$7 million in a Series A round led by MassMutual Ventures Southeast Asia, the startup announced in a Thursday press release.

Other investors in the round include Blackbird Ventures, Cocoon Capital, Entrepreneur First and SGInnovate, alongside angel investors.

See-Mode specialises in artificial intelligence (AI)-based medical software that improves stroke prediction. Its debut product, Augmented Vascular Analysis (AVA), is a medical AI software for automated analysis and reporting of vascular ultrasound scans.

With the latest capital raise, it hopes to bring its products to Europe and the US in the next year. The startup also plans to at least double its headcount, hiring talent  across various product roles, expanding its research and development (R&D) and engineering capabilities, and building up its core sales and business development team.

The startup is also broadening its partnerships with more research institutions around the world, to build scientific evidence for its R&D efforts.

"In the current economic environment, we are extremely heartened to have MassMutual Ventures coming on board to lead our Series A round, and to see all of our existing investors renewing their support in our team," said Milad Mohammadzadeh, co-founder of See-Mode.

DECODING ASIA

Navigate Asia in
a new global order

Get the insights delivered to your inbox.

Anvesh Ramineni, managing director at MassMutual Ventures, added: "There is an increasing need for transformative healthcare solutions, and we are confident that See-Mode's team and product capabilities will deliver as it continues to expand to other parts of the world."

Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

Copyright SPH Media. All rights reserved.